The Canadian Journal of Hospital Pharmacy · 1995 · 12 citations · 6 references
PharmacyPharmaceuticsPharmacologyChromatographic AnalysisParenteral Dosage FormsParenteral Drug DeliveryDrug DissolutionDrug SolubilityOpioid AnalgesicsParenteral CompatibilityParenteral FormulationsParenteral PreparationsHigh-performance Liquid ChromatographyHigh-performance Liquid Chromatography Method DevelopmentIntravenous FormulationsParenteral Formulation StabilityParenteral Formulations CompatibilityParenteral Solution CompatibilityParenteral Solution StabilityRoom Temperature Stability
ABSTRACT The co-administration of parenteral medications can greatly diminish patient discomfort by eliminating the need for multiple intravenous lines. Cancer patients on long-term parenteral morphine therapy often require the additional administration of either midazolam or haloperidol. Solutions of morphine sulfate in saline, dextrose and water were combined with commercially available midazolam or haloperidol solutions to determine the physical and chemical compatibilities of the mixtures. A high performance liquid chromatographic method was developed for the simultaneous determination of both morphine and midazolam, and morphine and haloperidol in these solutions. Both components of mixtures of morphine and midazolam were found to be stable for up to 14 days (retention of ≥90% initial concentration) at room temperature. Mixed solutions of morphine and haloperidol, on the other hand, exhibited immediate cloudiness and eventual precipitation of a haloperidol salt which would preclude their co-administration. RESUME L'administration conjointe de medicaments par voie parenterale peut reduire grandement l'inconfort des patients. On elimine ainsi le recours a des tubulures intraveineuses multiples. Les patients atteints de cancer qui recoivent de la morphine par voie parenterale pour de longues periodes ont souvent besoin de recevoir du midazolam ou de l'haloperidol. Du sulfate de morphine dans une solution saline, avec dextrose et eau, a ete ajoute a des solutions de midazolam ou d'haloperidol disponibles sur le marche, afin de determiner les compatibilites physiques et chimiques des melanges ainsi produits. On a eu recours a la chromatographie liquide a haute performance pour evaluer simultanement les melanges morphine-midazolam, et morphine-haloperidol dans ses solutions. Les deux composantes du melange morphine et midazolam sont restees stables pendant une periode allant jusqu'a 14 jours (conservation des concentrations initiales ≥ 90 %) a la temperature ambiante. Les solutions de morphine et d'haloperidol sont par contre devenues immediatement troubles et ont forme un precipite de sel d'haloperidol rendant ainsi leur administration conjointe impossible.
6
Subcutaneous infusions for control of cancer symptoms
Porter Storey, Herbert H. Hill, R Louis et al. · Journal of Pain and Symptom Management · 1990 · 140 citations · Full text
Medicine, Oncology, Pharmacology +13